David J. Yvars Group’s Humacyte HUMA Stock Holding History

David J. Yvars Group’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,750	Closed	-$109K	–	81
2024 Q2	$109K	Buy	+22,750	New	+$118K	0.07%	75

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

David J. Yvars Group's HUMA Position: Q3 2024 in Review

David J. Yvars Group sold out of Humacyte (HUMA) in Q3 2024, closing a stake of 22,750 shares — an estimated $109K sold.

David J. Yvars Group first reported a position in HUMA in Q2 2024 and held it in 1 quarter. The position peaked at $109K in Q2 2024. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

David J. Yvars Group reported no remaining Humacyte position as of Q3 2024 after selling out during the quarter.
David J. Yvars Group sold 22,750 Humacyte shares in Q3 2024, an estimated $109K.
David J. Yvars Group first reported a position in Humacyte in Q2 2024 and held it in 1 quarter.
David J. Yvars Group's Humacyte position peaked at $109K in Q2 2024.
143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on David J. Yvars Group's 13F filing for Q3 2024, filed 31 Oct 2024.